Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for use in infection management in bone and soft tissue, announces the launch of its SYNICEM hip, knee and shoulder preformed spacers in Canada.

SYNICEM antibiotic-loaded preformed spacers are designed to preserve articular space, limb length and joint stability during two-stage revision procedures, while aiding in the treatment of infection by bacteria sensitive to gentamicin. Precision-engineered for consistency and structural uniformity, they are sterile, ready-to-use in under a minute, and reduce the time demands and mechanical risks associated with traditional intra-operative moulded or handmade spacers. 

Available in a comprehensive range of sizes and styles for case-by-case flexibility, the SYNICEM spacer range includes a choice of Charnley and Müller hip spacer designs, and specific left and right geometries for each knee. SYNICEM spacers have been successfully used for more than 20 years in over 70 countries, helping surgeons save operative time and manage challenging infection cases.

Michael Harris, Chief Executive Officer of Biocomposites, said: "Making SYNICEM preformed antibiotic-loaded spacers available to surgeons in Canada, less than three months after launching them in the U.S., is a source of pride for the team at Biocomposites. The quality and consistency of the SYNICEM spacer range reflect our long-standing focus on precision engineering and dependable performance, to support clinicians and improve care for patients with complex needs."